158 filings
Page 2 of 8
SC TO-C
qrrcrnsght8oaoeb
8 Jan 19
Information about tender offer
5:08pm
SC14D9C
b85mi78 n6dh
7 Jan 19
Written communication relating to third party tender offer
5:09pm
SC TO-C
ldrpp02rd3ib7h5
7 Jan 19
Information about tender offer
2:59pm
8-K
fw2uifg
7 Jan 19
Entry into a Material Definitive Agreement
7:14am
8-K
55qz66v39wtwgbf1tw
2 Jan 19
Departure of Directors or Certain Officers
4:30pm
8-K
hr6wv2yla ml3fz3q
6 Dec 18
Regulation FD Disclosure
4:30pm
8-K
mfepvv7gzub 0k
27 Nov 18
FDA Approves VitrakviĀ®Ā (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion1,2
6:01am
8-K
o74bmg8tr28qzkxshr2e
8 Nov 18
Loxo Oncology Reports Third Quarter 2018 Financial Results
6:45am
UPLOAD
q79f5q1vqo
23 Oct 18
Letter from SEC
12:00am
8-K
8fi4kke0ia9e
17 Sep 18
Other Events
12:00am
CORRESP
c31 9y84rc
6 Sep 18
Correspondence with SEC
12:00am
UPLOAD
7r5ottcipthystbl9e
22 Aug 18
Letter from SEC
12:00am
S-8
mhv927v
9 Aug 18
Registration of securities for employees
4:39pm
8-K
edp0qv95
9 Aug 18
Loxo Oncology Reports Second Quarter 2018 Financial Results
6:46am
8-K
1ibhve6
14 Jun 18
Departure of Directors or Certain Officers
12:00am
8-K
1wrry
4 Jun 18
Regulation FD Disclosure
12:00am
8-K
uctpibieg ic4l
8 May 18
Loxo Oncology Reports First Quarter 2018 Financial Results
6:45am